Company research
Acer Therapeutics Inc.
CIK 1069308Updated Sep 25, 2026
Securities
Historical securities (2)
ACERW · NASDAQ · warrant · closed Apr 6, 2018OPXAW · NASDAQ · warrant · closed Jan 15, 2025Name history
Opexa Therapeutics, Inc. · through Sep 20, 2017PharmaFrontiers Corp. · through Jun 2, 2006PHARMAFRONTIERS CORP · through Oct 5, 2005SPORTAN UNITED INDUSTRIES INC · through Jul 1, 2004
ACERW price & chart
Historical security
This listing closed Apr 6, 2018. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,624,226Source | 36,256,951Source | 14,613,688Source | 21,465,511Source |
| Property, Plant and Equipment, NetUSD | 214,578Source | 114,112Source | 130,081Source | 193,974Source |
| GoodwillUSD | 7,647,267Source | 7,647,267Source | 7,647,267Source | 7,647,267Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,329,218Source | 12,710,762Source | 5,761,568Source | 12,077,640Source |
| Assets, CurrentUSD | 3,516,698Source | 28,088,616Source | 6,441,029Source | 12,884,996Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 679,461Source | 807,356Source |
| Operating Lease, Right-of-Use AssetUSD | 200,000Source | 400,000Source | 400,000Source | 600,000Source |
| Other Assets, NoncurrentUSD | 245,683Source | 406,956Source | 395,311Source | 620,674Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 28,385,498Source | 37,980,556Source | 6,389,354Source | 3,095,195Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,962Source | 1,431Source | 1,324Source | 1,010Source |
| Retained Earnings (Accumulated Deficit)USD | -140,747,269Source | -114,509,954Source | -99,135,961Source | -76,250,512Source |
| Stockholders' Equity Attributable to ParentUSD | -16,761,272Source | -1,723,605Source | 8,224,334Source | 18,370,316Source |
| Additional Paid in Capital, Common StockUSD | 123,984,035Source | 112,784,918Source | 107,358,971Source | 94,619,818Source |
| Liabilities and EquityUSD | 11,624,226Source | 36,256,951Source | 14,613,688Source | 21,465,511Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,951,700Source | 29,109,950Source | 6,145,546Source | 2,768,913Source |
| Operating Lease, Liability, CurrentUSD | 103,925Source | 184,340Source | 274,172Source | 263,392Source |
| Accounts Payable, CurrentUSD | 3,813,280Source | 1,405,734Source | 1,672,109Source | 561,090Source |
| Operating Lease, Liability, NoncurrentUSD | 145,665Source | 209,497Source | 90,139Source | 326,282Source |
| Other Liabilities, NoncurrentUSD | 145,665Source | 209,497Source | 243,808Source | 326,282Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,657,394Source | 2,428,193Source | 3,781,101Source | 1,944,431Source |
| Deferred Tax Liabilities, NetUSD | 122,156Source | 98,561Source | 86,491Source | 147,903Source |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -26,237,315Source | -15,373,993Source | -22,885,449Source | -29,417,969Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,840,499Source | 2,287,007Source | 2,224,146Source | 2,612,855Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,407,546Source | -266,375Source | 1,111,019Source | -472,739Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -30,251,898Source | -134,909Source | -17,027,415Source | -29,506,949Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -171,170Source | -54,944Source | -10,902Source | -178,967Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 171,170Source | 54,944Source | 10,902Source | 178,967Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,041,524Source | 7,139,047Source | 10,722,245Source | 92,272Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -10,381,544Source | 6,949,194Source | -6,316,072Source | -29,593,644Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,329,218Source | 12,710,762Source | 5,761,568Source | 12,077,640Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 136,500Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,840,499Source | 2,287,007Source | — | — |
| DepreciationUSD | 66,035Source | 70,913Source | 70,814Source | 58,282Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -46,668Source | 54,757Source | -96,202Source | 8,205Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -4,669Source | — | -3,981Source | -57,578Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 568,909Source | — | — |
| General and Administrative ExpenseUSD | 12,689,422Source | 10,700,334Source | 10,954,923Source | 16,046,423Source |
| GoodwillUSD | 7,647,267Source | 7,647,267Source | 7,647,267Source | 7,647,267Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 118,600Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | — | 471,267Source |
| Net Income (Loss) Attributable to ParentUSD | -26,237,315Source | -15,373,993Source | -22,885,449Source | -29,417,969Source |
| Nonoperating Income (Expense)USD | -1,623,056Source | 574,396Source | -82,624Source | 479,472Source |
| Operating ExpensesUSD | 24,614,259Source | 17,208,389Source | 22,802,825Source | 29,897,441Source |
| Operating Lease, ExpenseUSD | 200,000Source | 300,000Source | 300,000Source | 200,000Source |
| Proceeds from Issuance of Common StockUSD | 8,909,718Source | 3,139,047Source | 10,159,766Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 92,272Source |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Total RevenueUSD | — | 1,260,000Source | — | — |
| Operating Income (Loss)USD | -24,614,259Source | -15,948,389Source | -22,802,825Source | -29,897,441Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,237,315Source | -15,373,993Source | -22,885,449Source | -29,417,969Source |
| Earnings Per Share, BasicUSD per share | -1.66Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | -1.66Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,767,152Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,767,152Source | — | — | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -46,668Source | 54,757Source | -96,202Source | 8,205Source |
| General and Administrative ExpenseUSD | 12,689,422Source | 10,700,334Source | 10,954,923Source | 16,046,423Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | — | — | — | 471,267Source |
| Nonoperating Income (Expense)USD | -1,623,056Source | 574,396Source | -82,624Source | 479,472Source |
| Operating ExpensesUSD | 24,614,259Source | 17,208,389Source | 22,802,825Source | 29,897,441Source |
| Operating Lease, ExpenseUSD | 200,000Source | 300,000Source | 300,000Source | 200,000Source |
| Research and Development ExpenseUSD | 11,924,837Source | 6,508,055Source | 11,847,902Source | 13,851,018Source |